• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $DERM

    Journey Medical Corporation

    Subscribe to $DERM
    $DERM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Journey Medical Corporation develops and commercializes pharmaceutical products for the treatment of dermatological conditions. It markets generic prescription drugs for dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: journeymedicalcorp.com

    Recent Analyst Ratings for Journey Medical Corporation

    DatePrice TargetRatingAnalyst
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/28/2024$11.00Buy
    ROTH MKM
    2/25/2022$9.00Overweight
    Cantor Fitzgerald
    12/16/2021$15.00Buy
    Roth Capital
    12/7/2021$14.00Buy
    B. Riley Securities
    See more ratings

    Journey Medical Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President & CEO Maraoui Claude sold $33,065 worth of shares (4,834 units at $6.84), decreasing direct ownership by 0.21% to 2,348,313 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:52 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $16,478 worth of shares (2,409 units at $6.84), decreasing direct ownership by 1% to 203,557 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:34:22 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO Alloush Ramsey sold $19,542 worth of shares (2,857 units at $6.84), decreasing direct ownership by 0.56% to 504,817 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      5/5/25 5:31:11 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude was granted 350,000 shares, increasing direct ownership by 17% to 2,353,147 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      4/16/25 7:07:59 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph was granted 160,000 shares, increasing direct ownership by 348% to 205,966 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      4/16/25 7:06:23 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Alloush Ramsey claimed ownership of 507,674 shares (SEC Form 3)

      3 - Journey Medical Corp (0001867066) (Issuer)

      4/4/25 4:05:14 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $246,848 worth of shares (49,271 units at $5.01), decreasing direct ownership by 2% to 2,003,147 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/11/25 7:53:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $203,451 worth of shares (40,456 units at $5.03), decreasing direct ownership by 2% to 2,052,418 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/10/25 6:21:57 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Maraoui Claude sold $360,762 worth of shares (70,556 units at $5.11), decreasing direct ownership by 3% to 2,092,874 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/5/25 7:53:31 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO Benesch Joseph sold $7,084 worth of shares (1,365 units at $5.19), decreasing direct ownership by 3% to 45,966 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      2/24/25 4:01:12 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights

      Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint's lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of September 30, 2025 MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), an innovative biopharmaceutical company focused on acquiring and adva

      3/31/25 4:05:13 PM ET
      $CKPT
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea

      Initial distribution of Emrosi to pharmacies ongoing First prescriptions of Emrosi filled SCOTTSDALE, Ariz., March 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the launch of and the first prescriptions filled for Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the treatment of inflammatory lesions of rosacea in adults. Emrosi is

      3/24/25 8:30:00 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

      SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2024 financial results after the U.S. financial markets close on Wednesday, March 26, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 26, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S.

      3/19/25 4:01:56 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Participate in the 37th Annual ROTH Conference

      SCOTTSDALE, Ariz., March 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 37th Annual ROTH Conference, which is being held March 16-18, 2025 in Dana Point, California. Claude Maraoui, President and Chief Executive Officer, will participate in a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. A

      3/12/25 8:30:49 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea

      DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) achieved the co-primary and all secondary endpoints with no significant safety issues when administered once daily for 16 weeks Published data from two Phase 3 clinical trials demonstrated statistical superiority of DFD-29 over both Oracea® (doxycycline) capsules and placebo for IGA treatment success and the reduction of total lesion count, as well as significantly superior reduction in erythema compared to placebo in both studies U.S. FDA approved Emrosi™ (also known as DFD-29) for the treatment of inflammatory lesions of rosacea in adults in November 2024; launch exp

      3/5/25 4:01:06 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida

      SCOTTSDALE, Ariz., March 04, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that it will be exhibiting at the 2025 American Academy of Dermatology ("AAD") Annual Meeting, taking place March 7-11, 2025 in Orlando, Florida. Journey Medical plans to highlight the launch of Emrosi™ and showcase its line of prescription dermatology products. The FDA approved Emrosi for the treatment of inflammatory lesions of rosace

      3/4/25 4:01:50 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

      SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that its management team will host a conference call to provide an update on the commercial launch plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November of 2024. Emrosi was developed i

      1/23/25 8:30:42 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      11/29/24 2:00:25 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Journey Medical Corporation (Amendment)

      SC 13G/A - Journey Medical Corp (0001867066) (Subject)

      12/29/22 5:15:07 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      8/17/22 4:01:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Journey Medical Corporation

      SC 13G - Journey Medical Corp (0001867066) (Subject)

      2/11/22 5:15:13 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation SEC Filings

    See more
    • SEC Form DEFA14A filed by Journey Medical Corporation

      DEFA14A - Journey Medical Corp (0001867066) (Filer)

      4/29/25 4:07:56 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Journey Medical Corporation

      DEF 14A - Journey Medical Corp (0001867066) (Filer)

      4/29/25 4:06:47 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Journey Medical Corporation

      PRE 14A - Journey Medical Corp (0001867066) (Filer)

      4/18/25 4:01:23 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      4/3/25 7:31:22 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Journey Medical Corporation

      10-K - Journey Medical Corp (0001867066) (Filer)

      3/26/25 9:47:07 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      3/26/25 4:06:42 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      3/24/25 8:30:23 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      2/5/25 4:01:44 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Journey Medical Corporation

      10-Q - Journey Medical Corp (0001867066) (Filer)

      11/12/24 4:06:01 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Journey Medical Corp (0001867066) (Filer)

      11/12/24 4:05:20 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Journey Medical with a new price target

      Rodman & Renshaw initiated coverage of Journey Medical with a rating of Buy and set a new price target of $9.00

      8/22/24 7:21:37 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM resumed coverage on Journey Medical with a new price target

      ROTH MKM resumed coverage of Journey Medical with a rating of Buy and set a new price target of $11.00

      6/28/24 7:38:15 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Journey Medical with a new price target

      Cantor Fitzgerald initiated coverage of Journey Medical with a rating of Overweight and set a new price target of $9.00

      2/25/22 9:05:17 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Roth Capital initiated coverage on Journey Medical with a new price target

      Roth Capital initiated coverage of Journey Medical with a rating of Buy and set a new price target of $15.00

      12/16/21 6:55:51 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • B. Riley Securities initiated coverage on Journey Medical with a new price target

      B. Riley Securities initiated coverage of Journey Medical with a rating of Buy and set a new price target of $14.00

      12/7/21 6:10:10 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Journey Medical Corporation Leadership Updates

    Live Leadership Updates

    See more

    Journey Medical Corporation Financials

    Live finance-specific insights

    See more

    Journey Medical Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer

      SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General Counsel, to the position of Chief Operating Officer ("COO"). Mr. Alloush will continue to also serve as the Company's General Counsel. Claude Maraoui, President and Chief Executive Officer of Journey Medical, commented, "Ramsey's promotion to COO reflects

      4/1/25 4:01:16 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Michael C. Pearce to Board of Directors

      SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that on July 9, 2024, it appointed Michael C. Pearce to its Board of Directors. Mr. Pearce is a principal investor with an emphasis on healthcare. Since 2015, he has served as an advisor to EP Group and board member of its predecessor parent company, Evening Post Industries ("EPI"). At EPI, he served on the audit, compensation, and inves

      7/11/24 4:05:39 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer

      SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as the Company's Interim Chief Financial Officer since January 2023 and he served as the Company's Corporate Controller prior to that since November 2021. Claude Maraoui, Co-Founder, President and Chief

      5/1/24 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

      REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re

      11/1/23 8:00:00 AM ET
      $DERM
      $JSPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

      SCOTTSDALE, Ariz., Jan. 20, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or the "Company"), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Ernest (Ernie) De Paolantonio has notified the Company that, effective January 27, 2023, he will step down as Chief Financial Officer of Journey Medical to pursue another opportunity. The Company also today announced the appointment of Joseph M. Benesch as Interim Chief Financial Officer, effective January 27, 2023. Claude Maraoui, Co-Founder, President and Chief E

      1/20/23 4:01:30 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position

      JERUSALEM, July 18, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered peptides and therapeutic proteins, announced today the execution of the following key milestones: The U.S. Food and Drug Administration (FDA) has granted Entera's request for a Type C Meeting based on the revised phase 3 registrational study for lead clinical asset, EB613 (oral formulation of PTH (1-34, teriparatide), as the first oral anabolic drug to treat post-menopausal women with osteoporosis. The meeting is expected in H2 2022Following its End of Phase 2 Meeting with the FDA, Entera designed the pivotal study for EB613 as an 18 month double blind placebo-contro

      7/18/22 7:05:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy

      BOSTON and JERUSALEM, May 16, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced the appointment of Miranda Toledano, one of Entera's existing board members, as Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy, effective immediately. "Miranda is an accomplished leader in the biotechnology industry with almost 25 years of C-level leadership, principal investment and capital markets experience," commented Spiros Jamas, Chief Executive Officer of Entera Bio. "Ms. Toledano, as a member of our Board of Directors since 2018, has an extensive understanding of Entera's

      5/16/22 8:00:00 AM ET
      $CMPX
      $DERM
      $ENTX
      $NXGL
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical/Dental Instruments
    • Journey Medical Corporation to Announce First Quarter 2025 Financial Results on May 14, 2025

      SCOTTSDALE, Ariz., May 07, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter 2025 financial results after the U.S. financial markets close on Wednesday, May 14, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, May 14, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. s

      5/7/25 4:01:25 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights

      FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended December 31, 2024 were $56.1 million Met All Financial Guidance for 2024 Emrosi Phase 3 Clinical Trial Results Published in JAMA Dermatology Company to Hold Conference Call Today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 26, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approve

      3/26/25 4:01:00 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025

      SCOTTSDALE, Ariz., March 19, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2024 financial results after the U.S. financial markets close on Wednesday, March 26, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 26, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S.

      3/19/25 4:01:56 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Host Conference Call to Discuss U.S. Commercial Launch Plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

      SCOTTSDALE, Ariz., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that its management team will host a conference call to provide an update on the commercial launch plan for Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29. The FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults in November of 2024. Emrosi was developed i

      1/23/25 8:30:42 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the Treatment of Rosacea

      SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that the FDA has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg), formerly referred to as DFD-29, for the treatment of inflammatory lesions of rosacea in adults. Emrosi was developed in collaboration with Dr. Reddy's Laboratories Ltd. Claude Maraoui, Co-Founder, President, and Chief Executive Officer of Jo

      11/4/24 7:00:53 AM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SWK Holdings Provides Portfolio Update

      Company Announces Q3 Earnings and Conference Call Dates DALLAS, TX / ACCESSWIRE / October 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small- and mid-sized commercial-stage companies, provided today a portfolio update and announced the anticipated date of the third quarter earnings and conference call schedule.The Company intends to issue their third quarter financials after market close on November 14, 2024, and will host a conference call at 9:00 a.m. Central Time on November 15, 2024, to discuss the company's financial results for the quarter. Call details will be available in the quarterly results

      10/17/24 4:15:00 PM ET
      $BTCY
      $DERM
      $ELUT
      $ETON
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Journey Medical Corporation Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

      New Drug Application for DFD-29 to treat rosacea under FDA review; PDUFA goal date of November 4, 2024 Total revenues for the second quarter ended June 30, 2024 were $14.9 million, a 14% increase from the $13.0 million reported in the first quarter of 2024 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for

      8/12/24 4:01:35 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Journey Medical Corporation to Announce Second Quarter 2024 Financial Results on August 12, 2024

      SCOTTSDALE, Ariz., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its second quarter 2024 financial results after the U.S. financial markets close on Monday, August 12, 2024. Journey Medical management will conduct a conference call and audio webcast on Monday, August 12, 2024 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. should dial 1-866-777-2509 (domestic)

      8/6/24 4:01:38 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

      DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

      7/17/24 4:15:00 PM ET
      $BIOL
      $BTCY
      $DERM
      $ELUT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

      New Drug Application for DFD-29 to treat rosacea accepted for U.S. FDA review; PDUFA goal date of November 4, 2024 Total revenues for the first quarter ended March 31, 2024 were $13.0 million, a 7% increase from the $12.2 million reported in the first quarter of 2023 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., May 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company"), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical pr

      5/13/24 4:01:47 PM ET
      $DERM
      $FBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rosenwald Lindsay A Md bought $30,400 worth of shares (10,000 units at $3.04), increasing direct ownership by 7% to 144,245 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/27/24 7:00:16 AM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maraoui Claude bought $34,790 worth of shares (10,000 units at $3.48), increasing direct ownership by 0.46% to 2,163,430 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:03:29 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Justin Adam bought $104,100 worth of shares (30,000 units at $3.47), increasing direct ownership by 29% to 134,717 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:02:02 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rosenwald Lindsay A Md bought $68,000 worth of shares (20,000 units at $3.40), increasing direct ownership by 18% to 134,245 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      3/25/24 4:01:23 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Smith Justin Adam bought $98,340 worth of shares (33,000 units at $2.98), increasing direct ownership by 46% to 104,717 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      10/17/23 4:01:32 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Paley Jeffrey bought $44,700 worth of shares (15,000 units at $2.98), increasing direct ownership by 26% to 72,472 units (SEC Form 4)

      4 - Journey Medical Corp (0001867066) (Issuer)

      10/10/23 4:41:00 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Paley Jeffrey bought $89,100 worth of shares (30,000 units at $2.97), increasing direct ownership by 109% to 57,472 units

      4 - Journey Medical Corp (0001867066) (Issuer)

      9/25/23 4:01:37 PM ET
      $DERM
      Biotechnology: Pharmaceutical Preparations
      Health Care